Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adverum Biotechnologies, Inc. (ADVM)

0.66   -0.018 (-2.65%) 12-02 16:00
Open: 0.69 Pre. Close: 0.678
High: 0.695 Low: 0.641
Volume: 682,466 Market Cap: 66(M)

Technical analysis

as of: 2022-12-02 4:20:41 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.97     One year: 1.11
Support: Support1: 0.62    Support2: 0.52
Resistance: Resistance1: 0.83    Resistance2: 0.95
Pivot: 0.69
Moving Average: MA(5): 0.67     MA(20): 0.7
MA(100): 1.08     MA(250): 1.22
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 22.5     %D(3): 24.4
RSI: RSI(14): 35.8
52-week: High: 2.03  Low: 0.62
Average Vol(K): 3-Month: 427 (K)  10-Days: 292 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADVM ] has closed above bottom band by 19.3%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.7 - 0.7 0.7 - 0.7
Low: 0.63 - 0.64 0.64 - 0.64
Close: 0.65 - 0.66 0.66 - 0.67

Company Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Headline News

Fri, 25 Nov 2022
Adverum Biotechnologies : Failure to Satisfy Listing Rule - Form 8-K - Marketscreener.com

Thu, 10 Nov 2022
Adverum Biotechnologies GAAP EPS of -$0.40 misses by $0.06 (NASDAQ:ADVM) - Seeking Alpha

Fri, 04 Nov 2022
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$81m and insiders who purchased earlier this year lose another US$69k - Simply Wall St

Fri, 04 Nov 2022
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) - Yahoo Finance

Fri, 30 Sep 2022
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD - GlobeNewswire

Wed, 07 Sep 2022
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully - Simply Wall St

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 100 (M)
Shares Float 85 (M)
% Held by Insiders 3.6 (%)
% Held by Institutions 64.5 (%)
Shares Short 2,580 (K)
Shares Short P.Month 2,660 (K)

Stock Financials

EPS -1.58
EPS Est Next Qtl -0.32
EPS Est This Year -1.26
EPS Est Next Year -1.31
Book Value (p.s.) 2.08
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -23
Return on Equity (ttm) -56.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.82
Sales Per Share 0
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0
Operating Cash Flow -115 (M)
Levered Free Cash Flow -84 (M)

Stock Valuations

PE Ratio -0.42
PEG Ratio 0
Price to Book value 0.31
Price to Sales 0
Price to Cash Flow -0.58

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.